An Evernorth study found that in 2021, 25% of adults with ADHD did not receive any treatment, though this is a decrease from 38.5% in 2017. About 21.4% of adults with ADHD received both medication and behavioral therapy in 2021, up from 12.9% in 2017.
Child and adolescent mental health, palliative care and clinical AI are among opportunities that investors should consider closely this year an in the future.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company is licensing out technology from Australian digital health company TALi Digital to improve attention in early childhood. Akili will pay $37.5 million, including milestone payments and royalties.
Akili Interactive, a digital health company that got FDA clearance last year for its video game as treatment for ADHD, recently brought in $160 million in funding. It plans to use the funds to ramp up coverage of its flagship treatment and to develop digital treatments for other cognitive conditions.
Judges picked Atentiv as the winning pitch at MedCity Invest’s virtual conference. The Boston-based startup is building a game to improve attention in kids with ADHD.
After years of work, Akili received FDA clearance for its video game to be used as a treatment for ADHD. CEO Eddie Martucci shared what went into that process and what’s next.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Digital health company Akili Interactive received FDA de novo clearance for its digital therapeutic, a video game intended to improve attention among kids with ADHD.
The company's cell phone-sized device delivers low-level electric stimulation to the trigeminal nerve through a patch placed on a patient's forehead.
Panelists at the MedCity Engage conference in San Diego agreed that a growing shortage of mental health professionals mean that technology has a key role to play in improving behavioral health treatment.
By teaming up, SAP employees will be able to use Cognoa's app to screen their children for developmental delays in language, behavior and other areas.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Temasek led the Series C and another new investor took part in the round — Baillie Gifford. Other investors in the round included Amgen Ventures, M Ventures (the CVC fund of Merck KGaA, Darmstadt, Germany), JAZZ Venture Partners, Canepa Advanced Healthcare Fund, and Brooklands Capital Strategies.
What do Adzenys XR-ODT, Dyanavel, Vyvanse, Dexedrine, Concerta, QuiliChew and ProCentra have in common? They're all variations of either dextroamphetamine (Adderall) or methylphenidate (Ritalin). NLS Pharma thinks it's time for something new in the ADHD toolbox.
Massachusetts General Hospital and Memotext using digital health technology in an attempt to improve medication adherence in children with ADHD.
The ADHD market is booming, with an 8.5% CAGR and estimated sales of $13.9 billion in 2024. Despite the growth, the pipeline seems stuck, reformulating longer-release versions of two existing stimulant drugs.
The money will also boost Akili’s expansion into treatments for major depressive disorder and cognitive decline associated with multiple sclerosis and Parkinson’s disease.